Journey Medical Corp
NASDAQ:DERM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.92
7.96
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DERM stock under the Base Case scenario is 3.845 USD. Compared to the current market price of 5.085 USD, Journey Medical Corp is Overvalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Journey Medical Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DERM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Journey Medical Corp
Balance Sheet Decomposition
Journey Medical Corp
Current Assets | 46.5m |
Cash & Short-Term Investments | 23.9m |
Receivables | 10.5m |
Other Current Assets | 12.1m |
Non-Current Assets | 18.7m |
PP&E | 55k |
Intangibles | 18.7m |
Other Non-Current Assets | 6k |
Current Liabilities | 34.1m |
Accounts Payable | 14.9m |
Accrued Liabilities | 16.3m |
Other Current Liabilities | 3m |
Non-Current Liabilities | 19.7m |
Long-Term Debt | 19.7m |
Earnings Waterfall
Journey Medical Corp
Revenue
|
77.7m
USD
|
Cost of Revenue
|
-25.8m
USD
|
Gross Profit
|
51.9m
USD
|
Operating Expenses
|
-49.8m
USD
|
Operating Income
|
2.1m
USD
|
Other Expenses
|
-1.3m
USD
|
Net Income
|
844k
USD
|
Free Cash Flow Analysis
Journey Medical Corp
USD | |
Free Cash Flow | USD |
Journey Medical's Q2 2024 net product revenue was $14.9 million, keeping them on track for annual guidance of $55-60 million. Key products, QBREXZA and Accutane, showed prescription growth. Gross profit margins improved due to product mix and reduced royalties. The company achieved its fourth consecutive quarter of positive non-GAAP adjusted EBITDA, with $300,000 in Q2, while reducing SG&A expenses by 15%. Journey Medical focuses on securing FDA approval for DFD-29, targeting a launch in late Q1 2025. They plan to leverage market exclusivity until 2039, eyeing significant growth in the $1.2 billion rosacea treatment market.
What is Earnings Call?
DERM Profitability Score
Profitability Due Diligence
Journey Medical Corp's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Journey Medical Corp's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
DERM Solvency Score
Solvency Due Diligence
Journey Medical Corp's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Journey Medical Corp's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DERM Price Targets Summary
Journey Medical Corp
According to Wall Street analysts, the average 1-year price target for DERM is 9.308 USD with a low forecast of 8.08 USD and a high forecast of 11.55 USD.
Dividends
Current shareholder yield for DERM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. The company is headquartered in Scottsdale, Arizona and currently employs 90 full-time employees. The company went IPO on 2021-11-12. The company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company provides nine products that help treat and heal common skin conditions, such as Qbrexza, Accutane, Targadox, Ximino, Exelderm Cream and Solution, Ceracade Skin Emulsion, Luxamend Wound Cream, AMZEEQ and ZILXI. Its product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne; Exelderm Cream and Solution is an antifungal intended for topical use; Ceracade Skin Emulsion is used to treat dry skin conditions; AMZEEQ is used for the treatment of acne and ZILXI, for the treatment of rosacea.
Contact
IPO
Employees
Officers
The intrinsic value of one DERM stock under the Base Case scenario is 3.845 USD.
Compared to the current market price of 5.085 USD, Journey Medical Corp is Overvalued by 24%.